Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia

J. M. Donovan; K. Von Bergmann; K. D.R. Setchell; J. Isaacsohn; A. S. Pappu; D. R. Illingworth; T. Olson; S. K. Burke

doi:10.1007/s10620-005-2765-8

Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia

J. M. Donovan, K. Von Bergmann, K. D.R. Setchell, J. Isaacsohn, A. S. Pappu, D. R. Illingworth, T. Olson, S. K. Burke

Physiology & Pharmacology

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Colesevelam HCl is a potent bile acid-binding polymer. This study's aim was to determine effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Twenty-four patients (low-density lipoprotein cholesterol, 130 to 220 mg/dL) enrolled in an open-label, parallel-design study, entered an American Heart Association/National Cholesterol Education Program diet for 6 weeks and were randomized to colesevelam HCl, 2.3 or 3.8 g/day for 4 weeks. In an apparent dose-related manner, respective mean serum concentrations HCl of low-density lipoprotein cholesterol decreased by 10% (P < 0.01) and 13% (P = 0.05), mean total cholesterol levels decreased by 4.9% (P = 0.05) and 6.1% (P = 0.09), and total fecal bile acid excretion showed median changes of +324% (P < 0.05) and +316% (P < 0.05). Colesevelam HCl did not affect fecal neutral sterol or fecal fatty acid excretion; however, 24-hr urinary mevalonic acid levels significantly increased in both treatment groups (P < 0.05). The cholesterol-lowering action of colesevelam HCl appears to be mediated through increased bile acid excretion.

Original language	English (US)
Pages (from-to)	1232-1238
Number of pages	7
Journal	Digestive diseases and sciences
Volume	50
Issue number	7
DOIs	https://doi.org/10.1007/s10620-005-2765-8
State	Published - Jul 2005

Keywords

Bile acid sequestrant
Cholesterol
Colesevelam
Hypercholesterolemia
Low-density lipoprotein

ASJC Scopus subject areas

Physiology
Gastroenterology

Access to Document

10.1007/s10620-005-2765-8

Cite this

@article{670a2bdbc6a14c66945c20d3451c6d68,

title = "Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia",

abstract = "Colesevelam HCl is a potent bile acid-binding polymer. This study's aim was to determine effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Twenty-four patients (low-density lipoprotein cholesterol, 130 to 220 mg/dL) enrolled in an open-label, parallel-design study, entered an American Heart Association/National Cholesterol Education Program diet for 6 weeks and were randomized to colesevelam HCl, 2.3 or 3.8 g/day for 4 weeks. In an apparent dose-related manner, respective mean serum concentrations HCl of low-density lipoprotein cholesterol decreased by 10% (P < 0.01) and 13% (P = 0.05), mean total cholesterol levels decreased by 4.9% (P = 0.05) and 6.1% (P = 0.09), and total fecal bile acid excretion showed median changes of +324% (P < 0.05) and +316% (P < 0.05). Colesevelam HCl did not affect fecal neutral sterol or fecal fatty acid excretion; however, 24-hr urinary mevalonic acid levels significantly increased in both treatment groups (P < 0.05). The cholesterol-lowering action of colesevelam HCl appears to be mediated through increased bile acid excretion.",

keywords = "Bile acid sequestrant, Cholesterol, Colesevelam, Hypercholesterolemia, Low-density lipoprotein",

author = "Donovan, {J. M.} and {Von Bergmann}, K. and Setchell, {K. D.R.} and J. Isaacsohn and Pappu, {A. S.} and Illingworth, {D. R.} and T. Olson and Burke, {S. K.}",

note = "Funding Information: The authors acknowledge the Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA. This publication was supported by Sankyo Pharma Inc.",

year = "2005",

month = jul,

doi = "10.1007/s10620-005-2765-8",

language = "English (US)",

volume = "50",

pages = "1232--1238",

journal = "Digestive diseases and sciences",

issn = "0163-2116",

publisher = "Plenum Publishers",

number = "7",

}

TY - JOUR

T1 - Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia

AU - Donovan, J. M.

AU - Von Bergmann, K.

AU - Setchell, K. D.R.

AU - Isaacsohn, J.

AU - Pappu, A. S.

AU - Illingworth, D. R.

AU - Olson, T.

AU - Burke, S. K.

N1 - Funding Information: The authors acknowledge the Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA. This publication was supported by Sankyo Pharma Inc.

PY - 2005/7

Y1 - 2005/7

N2 - Colesevelam HCl is a potent bile acid-binding polymer. This study's aim was to determine effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Twenty-four patients (low-density lipoprotein cholesterol, 130 to 220 mg/dL) enrolled in an open-label, parallel-design study, entered an American Heart Association/National Cholesterol Education Program diet for 6 weeks and were randomized to colesevelam HCl, 2.3 or 3.8 g/day for 4 weeks. In an apparent dose-related manner, respective mean serum concentrations HCl of low-density lipoprotein cholesterol decreased by 10% (P < 0.01) and 13% (P = 0.05), mean total cholesterol levels decreased by 4.9% (P = 0.05) and 6.1% (P = 0.09), and total fecal bile acid excretion showed median changes of +324% (P < 0.05) and +316% (P < 0.05). Colesevelam HCl did not affect fecal neutral sterol or fecal fatty acid excretion; however, 24-hr urinary mevalonic acid levels significantly increased in both treatment groups (P < 0.05). The cholesterol-lowering action of colesevelam HCl appears to be mediated through increased bile acid excretion.

AB - Colesevelam HCl is a potent bile acid-binding polymer. This study's aim was to determine effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Twenty-four patients (low-density lipoprotein cholesterol, 130 to 220 mg/dL) enrolled in an open-label, parallel-design study, entered an American Heart Association/National Cholesterol Education Program diet for 6 weeks and were randomized to colesevelam HCl, 2.3 or 3.8 g/day for 4 weeks. In an apparent dose-related manner, respective mean serum concentrations HCl of low-density lipoprotein cholesterol decreased by 10% (P < 0.01) and 13% (P = 0.05), mean total cholesterol levels decreased by 4.9% (P = 0.05) and 6.1% (P = 0.09), and total fecal bile acid excretion showed median changes of +324% (P < 0.05) and +316% (P < 0.05). Colesevelam HCl did not affect fecal neutral sterol or fecal fatty acid excretion; however, 24-hr urinary mevalonic acid levels significantly increased in both treatment groups (P < 0.05). The cholesterol-lowering action of colesevelam HCl appears to be mediated through increased bile acid excretion.

KW - Bile acid sequestrant

KW - Cholesterol

KW - Colesevelam

KW - Hypercholesterolemia

KW - Low-density lipoprotein

UR - http://www.scopus.com/inward/record.url?scp=23044439087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044439087&partnerID=8YFLogxK

U2 - 10.1007/s10620-005-2765-8

DO - 10.1007/s10620-005-2765-8

M3 - Article

C2 - 16047465

AN - SCOPUS:23044439087

SN - 0163-2116

VL - 50

SP - 1232

EP - 1238

JO - Digestive diseases and sciences

JF - Digestive diseases and sciences

IS - 7

ER -

Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this